Head to Head Survey: Neurocrine Biosciences (NASDAQ:NBIX) versus Novartis (NYSE:NVS)

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) and Novartis (NYSE:NVS – Get Free Report) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Neurocrine Biosciences and Novartis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neurocrine Biosciences 18.98% 23.39% 16.22%
Novartis 18.11% 41.04% 14.45%

Valuation & Earnings

This table compares Neurocrine Biosciences and Novartis”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neurocrine Biosciences $2.86 billion 5.92 $478.60 million $6.74 24.84
Novartis $54.53 billion 5.62 $13.98 billion $5.24 30.65

Novartis has higher revenue and earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Neurocrine Biosciences and Novartis, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurocrine Biosciences 0 4 19 1 2.88
Novartis 3 9 6 0 2.17

Neurocrine Biosciences presently has a consensus target price of $202.59, suggesting a potential upside of 21.02%. Novartis has a consensus target price of $152.25, suggesting a potential downside of 5.19%. Given Neurocrine Biosciences’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than Novartis.

Volatility & Risk

Neurocrine Biosciences has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.

Summary

Neurocrine Biosciences beats Novartis on 10 of the 15 factors compared between the two stocks.

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.

About Novartis

(Get Free Report)

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.